Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



2 Lessons From Dendreon

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Was anyone else staring at Dendreon's (Nasdaq: DNDN  ) results in one window yesterday and the stock price in another and thinking something didn't seem right?

Turns out there was some weird trading of Dendreon's shares yesterday afternoon; this was right before trading on the stock was stopped ahead of presentation of the data for the company's prostate fighter, Provenge, at the American Urological Association's annual meeting.

The data looked good. Really good. But the stock was trading down 45% right before trading was stopped for the data presentation.

We already knew Provenge had passed its pivotal phase 3 trial, but the data confirmed that the treatment can get past the FDA and it suggests how well Provenge might sell.

Provenge extended survival by 4.1 months compared to placebo, which should be good enough for approval and fairly robust sales. The current treatment for advanced prostate cancer, sanofi-aventis' (NYSE: SNY  ) Taxotere, extends survival by about 2.5 months. In addition to the apparent longer survival, Taxotere is a nasty chemotherapy agent with horrible side effects compared to Provenge, which has relatively minimal side effects.

So what have we learned from yesterday?

  • When a CEO describes the data as "unambiguous," that probably means the full data set will look good. There are some CEOs out there that pump up weak data, but clearly Dendreon doesn't have one.
  • Put stop losses on stable companies like Johnson & Johnson (NYSE: JNJ  ) or Abbott Labs (NYSE: ABT  ) if you must, but stop losses can cause a lot of pain on more volatile stocks like Dendreon, Las Vegas Sands (NYSE: LVS  ) , and Citigroup (NYSE: C  ) .

If you missed getting in on the soap opera or got stopped-out with a cameo, there's still plenty of time to buy Dendreon. The company plans to amend its marketing application in the fourth quarter, which would push a potential FDA approval back until this time next year.

More Foolishness:

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a selection of the Income Investor newsletter. The Fool has a disclosure policy.

Read/Post Comments (5) | Recommend This Article (24)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 29, 2009, at 2:45 PM, prginww wrote:

    What a rollercoaster. Dizzying. --DG

  • Report this Comment On April 29, 2009, at 3:43 PM, prginww wrote:

    The situation was bold faced fraud and price manipulation, no doubt about it. The stock should have been halted for the entire trading day, well before the debacle.

  • Report this Comment On April 29, 2009, at 3:45 PM, prginww wrote:

    I just about fell out of my chair when I saw the stock price drop in half, I had bought 200 shares about an hour earlier. Yikes!! Sure was glad to see it recover over night and sold it first thing this morning.

  • Report this Comment On April 29, 2009, at 10:31 PM, prginww wrote:

    Great for the Longs but what a night it must have been before the next open.I was long Elan many moons ago and while it came back it was over months of agony.

    There were guys looking for option prices throughout this nightmare and finding the options symbols had

    changed or so I'm told.....

    Oh yeah.. trying to sleep with a position in DNDN Tuesday night ? Bela Lugosi,Boris Karloff,Peter Lorre,

    and your old girlfriend all hanging out by the window sill.


  • Report this Comment On April 30, 2009, at 10:34 AM, prginww wrote:

    "Potential" approval? The key word is "Potential". "Possible" $2 billion in sales? The key word is again "Possible". Folks, if you already made some money from DNDN, GET THE HECK OUT, and move on to others.

    Stocks like DNDN is so obvious of a SCAM stock. That's it. You guys should know what to do.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 887199, ~/Articles/ArticleHandler.aspx, 10/25/2016 12:21:24 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,176.53 -46.50 -0.26%
S&P 500 2,143.60 -7.73 -0.36%
NASD 5,286.24 -23.59 -0.44%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
ABT $40.31 Down -0.10 -0.25%
Abbott Laboratorie… CAPS Rating: *****
C $49.65 Up +0.07 +0.14%
Citigroup CAPS Rating: ***
JNJ $113.82 Up +0.21 +0.18%
Johnson and Johnso… CAPS Rating: ****
LVS $57.99 Up +0.04 +0.06%
Las Vegas Sands CAPS Rating: ****
SNY $37.36 Down -0.40 -1.06%
Sanofi CAPS Rating: *****